This site is intended for U.S. healthcare professionals.

Indication
IDHIFA® (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

LEARN HOW TO IDENTIFY, MONITOR, & MANAGE ARs ASSOCIATED WITH IDHIFA®

AR-Aid IDHIFA®

PATIENT MANAGEMENT TOOL

  1. Data on file, Celgene Corporation. Summit, New Jersey.